Connection

MALCOLM BRENNER to Cytotoxicity, Immunologic

This is a "connection" page, showing publications MALCOLM BRENNER has written about Cytotoxicity, Immunologic.
Connection Strength

1.439
  1. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther. 1998 Jun 10; 9(9):1303-11.
    View in: PubMed
    Score: 0.132
  2. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res. 2018 01; 6(1):47-58.
    View in: PubMed
    Score: 0.126
  3. CD40 ligand induces an antileukemia immune response in vivo. Blood. 1997 Sep 01; 90(5):1927-33.
    View in: PubMed
    Score: 0.125
  4. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
    View in: PubMed
    Score: 0.123
  5. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296.
    View in: PubMed
    Score: 0.123
  6. Bone marrow transplant recipients have defective MHC-unrestricted cytotoxic responses against cytomegalovirus in comparison with Epstein-Barr virus: the importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1). Blood. 1992 Jun 01; 79(11):3059-66.
    View in: PubMed
    Score: 0.087
  7. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood. 1989 Apr; 73(5):1351-8.
    View in: PubMed
    Score: 0.070
  8. Cytokine-induced enhancement of the susceptibility of hairy cell leukaemia lymphocytes to natural killer cell lysis. Br J Haematol. 1988 Sep; 70(1):37-41.
    View in: PubMed
    Score: 0.067
  9. Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Rep Med. 2024 Jul 16; 5(7):101628.
    View in: PubMed
    Score: 0.050
  10. Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood. 2003 Nov 15; 102(10):3815-21.
    View in: PubMed
    Score: 0.047
  11. Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol Blood Marrow Transplant. 2003 Apr; 9(4):273-81.
    View in: PubMed
    Score: 0.046
  12. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002 Mar 15; 99(6):2009-16.
    View in: PubMed
    Score: 0.043
  13. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002 Jan 15; 168(2):909-18.
    View in: PubMed
    Score: 0.042
  14. Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. Exp Hematol. 2001 Aug; 29(8):952-61.
    View in: PubMed
    Score: 0.041
  15. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5).
    View in: PubMed
    Score: 0.040
  16. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258.
    View in: PubMed
    Score: 0.030
  17. Engineered T cells for cancer treatment. Cytotherapy. 2014 Jun; 16(6):713-33.
    View in: PubMed
    Score: 0.024
  18. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer. 1993 May; 67(5):933-8.
    View in: PubMed
    Score: 0.023
  19. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18.
    View in: PubMed
    Score: 0.022
  20. IL2 activated killer cells may contribute to cytomegalovirus induced marrow hypoplasia after bone marrow transplantation. Bone Marrow Transplant. 1991 Feb; 7(2):81-7.
    View in: PubMed
    Score: 0.020
  21. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011 Mar 24; 117(12):3353-62.
    View in: PubMed
    Score: 0.020
  22. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct; 33(8):780-8.
    View in: PubMed
    Score: 0.019
  23. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood. 1989 Nov 15; 74(7):2335-42.
    View in: PubMed
    Score: 0.018
  24. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91.
    View in: PubMed
    Score: 0.018
  25. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma. J Immunother. 2009 Jun; 32(5):524-38.
    View in: PubMed
    Score: 0.018
  26. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402.
    View in: PubMed
    Score: 0.017
  27. CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul; 91(7):886-94.
    View in: PubMed
    Score: 0.014
  28. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood. 2003 Feb 01; 101(3):1007-14.
    View in: PubMed
    Score: 0.011
  29. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001 Feb 15; 97(4):835-43.
    View in: PubMed
    Score: 0.010
  30. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant. 1996 Feb; 17(2):243-7.
    View in: PubMed
    Score: 0.007
  31. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.